The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP-OLIGO study (WJOG11118L): Feasibility analysis of induction therapy and local ablative therapy.
 
Taichi Miyawaki
No Relationships to Disclose
 
Hirotsugu Kenmotsu
Honoraria - Amgen; AstraZeneca; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Kyowa Hakko Kirin; Lilly; Merck; MSD K.K; Nihonkayaku; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Loxo (Inst); Novartis (Inst)
 
Hideyuki Harada
No Relationships to Disclose
 
Yasuhisa Ohde
No Relationships to Disclose
 
Yasutaka Chiba
No Relationships to Disclose
 
Yusuke Kawanaka
No Relationships to Disclose
 
Yasuhiro Tsutani
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; CareNet; Chugai Pharma; Covidien; CSL Behring; Japan Blood Products Organization; Johnson & Johnson/Janssen; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; MiRTeL; Ono Pharmaceutical
Research Funding - Abbott Laboratories; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Japan Blood Products Organization; Kyowa Kirin International; Medtronic; Medtronic; Otsuka; Taiho Pharmaceutical
 
Kentaro Tanaka
Honoraria - Astrazeneca; Bristol-Myers Squibb/Ono Pharmaceutical; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; MSD; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Janssen
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline (Inst); MSD (Inst)
 
Keiji Matsumoto
No Relationships to Disclose
 
Masaki Oshima
No Relationships to Disclose
 
Satoru Miura
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Yuki Sato
Honoraria - AstraZeneca; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Daiichi Sankyo/Arqule; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Yukihiro Toi
No Relationships to Disclose
 
Koichi Azuma
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Takeda
 
Masafumi Yamaguchi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kazuhiko Nakagawa
Honoraria - AstraZeneca Japan; Bayer Yakuhin; Bristol Myers Squibb Company; Chugai Pharma; Daiichi Sankyo Co., Ltd.; Global Health Consulting Japan Co., Ltd.; Hisamitsu Pharmaceutical; Incyte; Janssen; Lilly Japan; M3; Medical Mobile Communications; Merck; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; The Yomiuri Shimbun; YODOSHA
Consulting or Advisory Role - Lilly Japan; Ono Pharmaceutical
Research Funding - A2 Healyhcare Corp. (Inst); Abbvie (Inst); Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Eisai (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Janssen (Inst); Japan Clinical Cancer Research Organization (Inst); Kobayashi Pharmaceutical (Inst); Labcorp Drug Development (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); Shionogi (Inst); SRL Medisearch Inc. (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Thoracic Oncology Research Group (Inst)
 
Nobuyuki Yamamoto
Honoraria - Abbvie; Acuuray; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Guardant Health; Janssen; Kyorin; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); Mebix (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)